chr12-2679450-G-A
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PP2PP3BP6BS2
The NM_000719.7(CACNA1C):c.5098G>A(p.Gly1700Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000122 in 1,560,548 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 11/19 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000719.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1C | ENST00000399603.6 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 5 | NM_001167623.2 | ENSP00000382512.1 | ||
CACNA1C | ENST00000399655.6 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 1 | NM_000719.7 | ENSP00000382563.1 | ||
CACNA1C | ENST00000682544.1 | c.5332G>A | p.Gly1778Ser | missense_variant | 44/50 | ENSP00000507184.1 | ||||
CACNA1C | ENST00000406454.8 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/48 | 5 | ENSP00000385896.3 | |||
CACNA1C | ENST00000399634.6 | c.5065G>A | p.Gly1689Ser | missense_variant | 41/47 | 5 | ENSP00000382542.2 | |||
CACNA1C | ENST00000683824.1 | c.5263G>A | p.Gly1755Ser | missense_variant | 43/48 | ENSP00000507867.1 | ||||
CACNA1C | ENST00000347598.9 | c.5242G>A | p.Gly1748Ser | missense_variant | 44/49 | 1 | ENSP00000266376.6 | |||
CACNA1C | ENST00000344100.7 | c.5221G>A | p.Gly1741Ser | missense_variant | 42/47 | 1 | ENSP00000341092.3 | |||
CACNA1C | ENST00000327702.12 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/48 | 1 | ENSP00000329877.7 | |||
CACNA1C | ENST00000399617.6 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/48 | 5 | ENSP00000382526.1 | |||
CACNA1C | ENST00000682462.1 | c.5188G>A | p.Gly1730Ser | missense_variant | 42/47 | ENSP00000507105.1 | ||||
CACNA1C | ENST00000683781.1 | c.5188G>A | p.Gly1730Ser | missense_variant | 42/47 | ENSP00000507434.1 | ||||
CACNA1C | ENST00000683840.1 | c.5188G>A | p.Gly1730Ser | missense_variant | 42/47 | ENSP00000507612.1 | ||||
CACNA1C | ENST00000683956.1 | c.5188G>A | p.Gly1730Ser | missense_variant | 42/47 | ENSP00000506882.1 | ||||
CACNA1C | ENST00000399638.5 | c.5182G>A | p.Gly1728Ser | missense_variant | 43/48 | 1 | ENSP00000382547.1 | |||
CACNA1C | ENST00000335762.10 | c.5173G>A | p.Gly1725Ser | missense_variant | 43/48 | 5 | ENSP00000336982.5 | |||
CACNA1C | ENST00000399606.5 | c.5158G>A | p.Gly1720Ser | missense_variant | 43/48 | 1 | ENSP00000382515.1 | |||
CACNA1C | ENST00000399621.5 | c.5155G>A | p.Gly1719Ser | missense_variant | 42/47 | 1 | ENSP00000382530.1 | |||
CACNA1C | ENST00000399637.5 | c.5155G>A | p.Gly1719Ser | missense_variant | 42/47 | 1 | ENSP00000382546.1 | |||
CACNA1C | ENST00000402845.7 | c.5155G>A | p.Gly1719Ser | missense_variant | 42/47 | 1 | ENSP00000385724.3 | |||
CACNA1C | ENST00000399629.5 | c.5149G>A | p.Gly1717Ser | missense_variant | 42/47 | 1 | ENSP00000382537.1 | |||
CACNA1C | ENST00000682336.1 | c.5140G>A | p.Gly1714Ser | missense_variant | 42/47 | ENSP00000507898.1 | ||||
CACNA1C | ENST00000399591.5 | c.5122G>A | p.Gly1708Ser | missense_variant | 41/46 | 1 | ENSP00000382500.1 | |||
CACNA1C | ENST00000399595.5 | c.5122G>A | p.Gly1708Ser | missense_variant | 41/46 | 1 | ENSP00000382504.1 | |||
CACNA1C | ENST00000399649.5 | c.5116G>A | p.Gly1706Ser | missense_variant | 41/46 | 1 | ENSP00000382557.1 | |||
CACNA1C | ENST00000399597.5 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 1 | ENSP00000382506.1 | |||
CACNA1C | ENST00000399601.5 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 1 | ENSP00000382510.1 | |||
CACNA1C | ENST00000399641.6 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 1 | ENSP00000382549.1 | |||
CACNA1C | ENST00000399644.5 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | 1 | ENSP00000382552.1 | |||
CACNA1C | ENST00000682835.1 | c.5098G>A | p.Gly1700Ser | missense_variant | 42/47 | ENSP00000507282.1 | ||||
CACNA1C | ENST00000683482.1 | c.5089G>A | p.Gly1697Ser | missense_variant | 42/47 | ENSP00000507169.1 | ||||
CACNA1C | ENST00000682686.1 | c.5065G>A | p.Gly1689Ser | missense_variant | 41/46 | ENSP00000507309.1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152176Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000580 AC: 11AN: 189716Hom.: 0 AF XY: 0.0000690 AC XY: 7AN XY: 101378
GnomAD4 exome AF: 0.000132 AC: 186AN: 1408372Hom.: 0 Cov.: 31 AF XY: 0.000133 AC XY: 92AN XY: 694264
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152176Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74332
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 18, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 21, 2024 | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function - |
Timothy syndrome;C2678478:Brugada syndrome 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 29, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1700 of the CACNA1C protein (p.Gly1700Ser). This variant is present in population databases (rs761966966, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CACNA1C-related conditions. ClinVar contains an entry for this variant (Variation ID: 526905). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CACNA1C protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 01, 2019 | Variant summary: CACNA1C c.5098G>A (p.Gly1700Ser) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.6e-05 in 216132 control chromosomes (gnomAD). The observed variant frequency is approximately 6 fold of the estimated maximal expected allele frequency for a pathogenic variant in CACNA1C causing Arrhythmia phenotype (1e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.5098G>A in individuals affected with Arrhythmia and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely benign. - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 21, 2024 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at